Lv2
142 积分 2024-07-28 加入
[The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer]
9天前
已完结
From trial to practice: real-world outcomes of neoadjuvant chemoimmunotherapy versus chemotherapy ± radiotherapy in resectable locally advanced NSCLC
9天前
已完结
A Lost Opportunity: Underutilization of Systemic Therapy in T3N0M0 Non-small Cell Lung Cancer
9天前
已完结
Efficacy and safety of a low-dose nivolumab regimen (240 mg) as neoadjuvant immunochemotherapy in Chinese patients with resectable non-small cell lung cancer: a prospective single-arm, exploratory study
9天前
已完结
Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer
9天前
已完结
[The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer]
9天前
已完结
Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England
9天前
已完结
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
9天前
已完结
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery
9天前
已完结
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China
9天前
已完结
皖公网安备34019202002308
